PubRank

Marybeth S Hughes

Author PubWeight™ 117.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 16.96
2 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008 10.13
3 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 9.24
4 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011 9.19
5 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011 9.03
6 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
7 Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006 7.40
8 Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007 5.51
9 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013 4.80
10 CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012 4.56
11 Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005 3.73
12 High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003 3.39
13 T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010 3.29
14 Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005 2.84
15 Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008 2.15
16 CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010 1.92
17 High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008 1.74
18 Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013 1.67
19 Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005 1.26
20 Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013 1.09
21 Pseudo-Meigs' syndrome secondary to isolated colorectal metastasis to ovary: a case report and review of the literature. Gynecol Oncol 2004 1.00
22 Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother 2006 1.00
23 A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 2012 0.96
24 The role of surgery in the management of patients with refractory chronic granulomatous disease colitis. Dis Colon Rectum 2013 0.94
25 Acupuncture treatment for persistent hiccups in patients with cancer. J Altern Complement Med 2010 0.89
26 Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother 2010 0.89
27 Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J Surg 2012 0.88
28 The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008 0.87
29 Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol 2009 0.85
30 Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery 2011 0.84
31 Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2009 0.83
32 von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms. Surgery 2012 0.82
33 Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery 2011 0.81
34 Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg 2013 0.81
35 Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit? World J Surg 2012 0.81
36 Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. Endocrine 2010 0.77
37 Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma. Diagn Cytopathol 2013 0.75
38 Image of the month. Cystic parathyroid adenoma. Arch Surg 2010 0.75